We still need the "RC220 Toxicology and Safety Pharmacology" data. Then patent lodgements, ethics approval, trial site onboarding etc. Would not expect first patient before Q2 CY24.
Near term SP inflection points more likely to be Sheba 2.0 results or licensing agreement.
- Forums
- ASX - By Stock
- Ann: RC220 Peripheral Infusion Safety Confirmed
We still need the "RC220 Toxicology and Safety Pharmacology"...
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.81 |
Change
-0.010(0.55%) |
Mkt cap ! $307.3M |
Open | High | Low | Value | Volume |
$1.83 | $1.84 | $1.78 | $271.2K | 150.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $1.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.81 | 349 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.800 |
2 | 1742 | 1.780 |
1 | 3914 | 1.775 |
1 | 1392 | 1.770 |
4 | 2287 | 1.765 |
Price($) | Vol. | No. |
---|---|---|
1.805 | 349 | 1 |
1.810 | 4100 | 1 |
1.815 | 703 | 1 |
1.820 | 703 | 1 |
1.825 | 2703 | 2 |
Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |